CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

Institut de Recherche pour le Développement operates as a scientific and technical public institution which provides information, expertise, support and training in production performance. It performs research centered on the relationship between human beings and its environment in intertropical areas. In that context the IRD implements research projects on sleeping sickness and the vectors transmitting the disease. The company is headquartered in Marseille, France.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Thiogenesis Therapeutics, Inc. engages in the development of novel compounds that are based on thiols, thiol derivatives or S-H groups. The company was founded by Patrice P. Rioux and Vincent P. Stanton and is headquartered in Belmont, MA.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Seasun Biomaterials, Inc. provides NGS services and real time PCR based diagnostic products. Its products and services include diagnostics, therapeutics, genome sequencing, transcriptome, and metagenome. The company was founded by Hee Gyeong Park on May 20, 2012 and is headquartered in Daejeon, South Korea.

Dr. Soliman Fakeeh Hospital is a private company headquartered in Jeddah, Saudi Arabia, that provides medical services. Mazen Soliman Abdul Qader Fakeeh is the current CEO of the firm.

Assistance Publique H��pitaux de Marseille is a private company headquartered in Marseille, France, specializing in general medical and surgical hospitals.

Part of Philip Morris International, Inc., Philip Morris Products SA is a company headquartered in Neuch?tel, Switzerland. The firm provides tobacco stemming and re drying services.

Sulfagenix and its wholly-owned subsidiary, Sulfagenix Australia, are built on decades of research on modifying existing molecules to improve safety, bioavailability, and efficacy for new uses. SG1002, the company’s lead molecule, is a precursor to a natural-occurring molecule, hydrogen sulfide, for which deficits have been shown to exist in a number of serious diseases, including cardiovascular disease, type II diabetes, cancer, hypertension, Alzheimer’s Disease, asthma, and wound healing. In addition, sulfur deficiencies in the diet may be directly contributing to these diseases. Patient studies in Mexico demonstrated safety and generated encouraging results in several disease conditions including infertility, cancer, and hypercholesterolemia. Sulfagenix’s lead product, SG1002, is being developed in Phase I clinical trial (http://www.clinicaltrials.gov/ct2/show/NCT01989208) in Australia by Sulfagenix Australia to treat problems associated with heart failure.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Eumentis Therapeutics, Inc. is an American company located in Newton, MA, that manufactures novel drugs. The firm was founded by Mark A. Tepper, who is currently the CEO of the company.\nThe company says this about itself: EuMentis Therapeutics Inc. is a privately held clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat neuropsychiatric and neurodevelopmental conditions with high unmet need. The company’s most advanced product candidate, EM-221, is a best-in-class oral PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum. EuMentis plans to initiate a Phase 2 study of EM-221 for the treatment of Tourette syndrome in the second half of 2023. EuMentis is also developing EM-113, an uncompetitive fast-off NMDA receptor antagonist for the treatment of autism spectrum disorder patients with elevated brain glutamate levels as determined by using its proprietary biomarker patient selection strategy. EuMentis is also expanding its pipeline through the development of novel fast-off NMDAR antagonists for treatment of multiple conditions in which elevated glutamate levels contribute to the pathophysiology, including traumatic brain injury (TBI), at present funded by an award from the United States Department of Defense, autism, and other neuropsychiatric and neurodevelopmental conditions.